Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    GSK breathes hope into respiratory biz in country

    By ZHOU WENTING in Shanghai | China Daily | Updated: 2023-04-27 09:54
    Share
    Share - WeChat

    Global biopharmaceutical company GlaxoSmithKline is scheduled to submit market approvals in China for about 15 new drugs and indications over the next three years and more than 20 clinical research projects will be conducted in the country, said a senior executive of the company.

    Yu Jinyi, vice-president and head of respiratory for GSK China. [Photo provided to chinadaily.com.cn]

    Some are innovative solutions in the respiratory field, a key category of the United Kingdom-based company's portfolio, with quantity and frequency ranking high among the top multinational pharmaceutical giants, said Yu Jinyi, vice-president and head of respiratory for GSK China, during an interview with China Daily on April 19.

    "The fast progress and ambitious plans benefit from the country's constantly deepening healthcare reforms, especially the accelerated approval and supervision of innovative medicines," said Yu.

    For the company's respiratory business, where it has marketed 16 products based on five decades of expertise, China is one of the prioritized markets and a strategic key market with the layout continuously upgraded as respiratory diseases show a rising trend in the country. The government has improved medical insurance coverage and the people's health awareness has increased, said Yu.

    A paper by Chinese researchers published in The Lancet in 2019 showed that China had 45.7 million asthma patients aged 20 and older and 15 million asthma sufferers aged below 20.

    "Voices from the China market are significant for the company at a global level, from formulating macro strategies to discussing the global prediction of a particular brand or which tactics to use," he said.

    Also, constant investment in the China market will surely support research and development, clinical research and marketing, added Yu.

    Clinical research in the country will be further accelerated as an approach to fulfill the company's goal to market new drugs in the country simultaneously with its global goals.

    For example, in a clinical study regarding the first inhalation therapy that only needs to be taken once daily to treat chronic obstructive pulmonary disease (COPD), which was marketed in China in 2019, Chinese patients were recruited at the same time research kicked off globally.

    GSK currently has two potential COPD and two potential asthma trials with Chinese patients, Yu said.

    China's inhalation therapy market approval came two years after it obtained market approval globally, far more rapidly than the situation in previous years. He said more shortened time gaps will be witnessed soon.

    Novel models, including those involving digital technologies, have also been adopted to explore new channels to benefit more patients, said Yu.

    For instance, the company has partnered with the Guangzhou Institute of Respiratory Health since 2017 to establish a collaborative network and database for managing asthma patients in China.

    The collaboration entered into the second phase last year to recruit 110 hospitals to join and register clinical data for approximately 18,000 asthma sufferers, aiming to ultimately improve the level of disease control of such patients in the country.

    Yu said the company is taking digital approaches in patient management and doctor education, and hopefully, more programs will be deployed to realize an elevation in education efficiency for doctors in the near future.

    Shen Huahao, vice-chairman of the respiratory branch of the Chinese Medical Association, said that more efforts should be made to popularize standard medical treatment for asthma patients at a grassroots level.

    The control rate of asthma in urban regions is only 28.5 percent, and the rate is lower in rural areas due to the huge gap in medical resources, said Shen, who is also director of the department of respiratory and critical care medicine at the Second Affiliated Hospital with Zhejiang University School of Medicine.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    中文无码字慕在线观看| 久久久久久亚洲精品无码| 国产精品热久久无码av| 中文字幕一区二区三区在线不卡 | 中文字幕日韩一区二区三区不卡| 久久久久无码精品国产不卡 | 亚洲国产精品无码专区影院 | 无码任你躁久久久久久老妇App| 无码乱码观看精品久久| 无码AV波多野结衣久久| 最近2019中文字幕大全第二页| 亚洲VA中文字幕无码一二三区| 精品无码一区在线观看| 亚洲av无码无在线观看红杏| 欧美麻豆久久久久久中文| 欧美日韩中文字幕2020| 中文字幕无码第1页| 无码人妻精品一区二区蜜桃AV| 久久精品无码专区免费东京热| 亚洲AV无码国产丝袜在线观看| 日韩精品无码视频一区二区蜜桃| 日韩欧群交P片内射中文| 亚洲一级特黄大片无码毛片| 日韩少妇无码喷潮系列一二三| 久久国产精品无码网站| 国产高清无码视频| 精品无人区无码乱码大片国产| 国产精品无码无需播放器| 久久Av无码精品人妻系列| 波多野42部无码喷潮在线 | 日韩亚洲国产中文字幕欧美| 精品无码三级在线观看视频 | 中文字幕乱码人在线视频1区| 无码人妻久久一区二区三区蜜桃 | 国产 欧美 亚洲 中文字幕| 天天看高清无码一区二区三区| 日韩精选无码| 国产乱码精品一区二区三区中文| 中文字幕国产在线| 少妇无码太爽了在线播放| 中文人妻无码一区二区三区|